{
  "publisher": "Aero Clinic",
  "url": "https://www.cagri.co.uk/weight-loss-plans",
  "currency": "GBP",
  "included_in_every_price": [],
  "note": "Aero prices, availability and service inclusions are unconfirmed. No amounts in this feed are a live offer. Use a written provider quote for financial planning.",
  "plans": [
    {
      "name": "Mounjaro",
      "active_ingredient": "tirzepatide",
      "maker": "Eli Lilly",
      "format": "Weekly injection",
      "url": "https://www.cagri.co.uk/mounjaro",
      "price_from_gbp_per_month": null,
      "doses": [
        {
          "dose": "2.5 mg",
          "price_gbp_per_month": null,
          "stage": "Starter dose, weeks 1 to 4"
        },
        {
          "dose": "5 mg",
          "price_gbp_per_month": null,
          "stage": "First maintenance dose"
        },
        {
          "dose": "7.5 mg",
          "price_gbp_per_month": null,
          "stage": "Optional step"
        },
        {
          "dose": "10 mg",
          "price_gbp_per_month": null,
          "stage": "Maintenance dose"
        },
        {
          "dose": "12.5 mg",
          "price_gbp_per_month": null,
          "stage": "Optional step"
        },
        {
          "dose": "15 mg",
          "price_gbp_per_month": null,
          "stage": "Highest dose"
        }
      ],
      "main_trial": {
        "name": "SURMOUNT-1",
        "participants": 2539,
        "weeks": 72,
        "dose": "15 mg",
        "mean_weight_loss_pct_all_participants": 20.9,
        "placebo_pct": 3.1,
        "source": "https://doi.org/10.1056/NEJMoa2206038"
      },
      "nhs": "limited, phased access"
    },
    {
      "name": "Wegovy",
      "active_ingredient": "semaglutide",
      "maker": "Novo Nordisk",
      "format": "Weekly injection",
      "url": "https://www.cagri.co.uk/wegovy",
      "price_from_gbp_per_month": null,
      "doses": [
        {
          "dose": "0.25 mg",
          "price_gbp_per_month": null,
          "stage": "Starter dose, weeks 1 to 4"
        },
        {
          "dose": "0.5 mg",
          "price_gbp_per_month": null,
          "stage": "Step 2"
        },
        {
          "dose": "1 mg",
          "price_gbp_per_month": null,
          "stage": "Step 3"
        },
        {
          "dose": "1.7 mg",
          "price_gbp_per_month": null,
          "stage": "Step 4"
        },
        {
          "dose": "2.4 mg",
          "price_gbp_per_month": null,
          "stage": "Maintenance dose"
        },
        {
          "dose": "7.2 mg",
          "price_gbp_per_month": null,
          "stage": "Additional maintenance option after prescribing review",
          "presentation_note": "UK product information includes a 7.2 mg single-dose pen and an alternative of three 2.4 mg injections. Confirm the prescribed presentation and pack quantity.",
          "source": "https://www.medicines.org.uk/emc/product/102093/smpc"
        }
      ],
      "main_trial": {
        "name": "STEP 1",
        "participants": 1961,
        "weeks": 68,
        "dose": "2.4 mg",
        "mean_weight_loss_pct_all_participants": 14.9,
        "placebo_pct": 2.4,
        "source": "https://doi.org/10.1056/NEJMoa2032183"
      },
      "nhs": "specialist services only"
    },
    {
      "name": "Wegovy pill",
      "active_ingredient": "oral semaglutide",
      "maker": "Novo Nordisk",
      "format": "Daily tablet",
      "url": "https://www.cagri.co.uk/wegovy-tablets",
      "price_from_gbp_per_month": null,
      "doses": [
        {
          "dose": "1.5 mg",
          "price_gbp_per_month": null,
          "stage": "Starter dose, first month"
        },
        {
          "dose": "4 mg",
          "price_gbp_per_month": null,
          "stage": "Step 2"
        },
        {
          "dose": "9 mg",
          "price_gbp_per_month": null,
          "stage": "Step 3"
        },
        {
          "dose": "25 mg",
          "price_gbp_per_month": null,
          "stage": "Maintenance dose"
        }
      ],
      "main_trial": {
        "name": "OASIS 4",
        "participants": 307,
        "weeks": 64,
        "dose": "25 mg",
        "mean_weight_loss_pct_all_participants": 13.6,
        "placebo_pct": 2.2,
        "source": "https://doi.org/10.1056/NEJMoa2500969"
      },
      "nhs": "not available on the NHS"
    },
    {
      "name": "Foundayo pill",
      "active_ingredient": "orforglipron",
      "maker": "Eli Lilly",
      "format": "Daily tablet",
      "url": "https://www.cagri.co.uk/foundayo",
      "price_from_gbp_per_month": null,
      "doses": [
        {
          "dose": "0.8 mg"
        },
        {
          "dose": "2.5 mg"
        },
        {
          "dose": "5.5 mg"
        },
        {
          "dose": "9 mg"
        },
        {
          "dose": "14.5 mg"
        },
        {
          "dose": "17.2 mg"
        }
      ],
      "main_trial": {
        "name": "ATTAIN-1",
        "participants": 3127,
        "weeks": 72,
        "dose": "36 mg capsule (equivalent to the 17.2 mg tablet)",
        "mean_weight_loss_pct_all_participants": 11.2,
        "placebo_pct": 2.1,
        "source": "https://doi.org/10.1056/NEJMoa2511774"
      },
      "nhs": "not available on the NHS"
    }
  ],
  "clinical_review_status": "pending",
  "source_content_date": "2026-10-15",
  "price_status": "unconfirmed",
  "ordering_status": "not-open"
}